Posts

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Authors: Kevin P. Hill
JAMA, 23 June 2015

IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease.

Authors: Jessica Margaret Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
International Reviews of Immunology, 2015

The impact of the endogenous cannabinoids (AEA, 2-AG, PEA, and virodamine) on the immune cell expressed cannabinoid receptors (CB1, CB2, TRPV-1, and GPR55) and consequent regulation of immune function is an exciting area of research with potential implications in the preventio…

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Authors: John Peter Zajicek, Jeremy C. Hobart, Anita Slade, David Barnes, Paul G. Mattison
Journal of Neurology, Neurosurgery, & Psychiatry, November 2012

OBJECTIVE: Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of pr…

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Authors: Jody Corey-Bloom, Tanya Wolfson, Anthony Gamst, Shelia Jin, Thomas D. Marcotte, et al
CMAJ, 10 July 2012

BACKGROUND: Spasticity is a common and poorly controlled symptom of multiple sclerosis. Our objective was to determine the short-term effect of smoked cannabis on this symptom. METHODS: We conducted a placebo-controlled, crossover trial involving adult patients with multiple s…

Role of cannabinoids in multiple sclerosis.

Authors: John P. Zajicek, Vicentiu I. Apostu
CNS Drugs, March 2011

Although extracts from the cannabis plant have been used medicinally for thousands of years, it is only within the last 2 decades that our understanding of cannabinoid physiology and the provision of evidence for therapeutic benefit of cannabinoids has begun to accumulate. Thi…

Cannabis use in palliative care – an examination of the evidence and the implications for nurses.

Authors: Anita J Green, Kay De‐Vries
Journal of Clinical Nursing, September 2010

AIM AND OBJECTIVE: Examine the pharmaceutical qualities of cannabis including a historical overview of cannabis use. Discuss the use of cannabis as a clinical intervention for people experiencing palliative care, including those with life-threatening chronic illness such as mu…

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

Authors: C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler
Multiple Sclerosis Journal, 1 August 2004

The majority of patients with multiple sclerosis (MS) develop troublesome lower urinary tract symptoms (LUTS). Anecdotal reports suggest that cannabis may alleviate LUTS, and cannabinoid receptors in the bladder and nervous system are potential pharmacological targets. In an o…

Chronic Cannabis Use in the Compassionate Investigational New Drug Program

Authors: Ethan Russo, Mary Lynn Mathre, Al Byrne, Robert Velin, Paul J. Bach, Juan Sanchez-Ramos, et al
Journal of Cannabis Therapeutics, 2002

The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic bepnefits and adverse effects of prolonged use of “medical marijuana” in a cohort of seriously ill patients. Use of cannabis was approved through the Compassionate Inves-tigational New…